News & Videos - PALISADE BIO INC.

You are currently viewing all stock exchange news of the financial instrument PALISADE BIO INC. regarding all markets in all languages.

> News GlobeNewsWire published a news.

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China • • GlobeNewsWire • Stocks

CARLSBAD, Calif. and SHANGHAI, China, May 07, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), and co-development partner Newsoara today announce completion of a Phase 2 clinical trial evaluating lead drug candidate LB1148 for accelerating return of bowel function associated with gastrointestinal (GI) surgery. The PROFILE study in China is a randomized, double-blind, multicenter, Phase 2 trial that has enrolled over 120 patients undergoing elective bowel resection. Patients received...

Thank you Chart

> News GlobeNewsWire published a news.

Palisade Bio Hosting Key Opinion Leader Webinar on LB1148, an Oral Serine Protease Inhibitor for Postoperative GI Dysfunction • • GlobeNewsWire • Stocks

CARLSBAD, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it will host a key opinion leader (KOL) webinar event on LB1148, the Company’s lead asset for indications associated with GI Surgery, on Thursday, May 13, 2021 at 1:00pm Eastern Time. The webinar will feature presentations by KOLs Steven Wexner, M.D., Cleveland Clinic, and Mark A....

Thank you Chart